Hospital access to Mark Cuban Cost Plus Drugs and other alternative suppliers will be expanded through a new strategic partnership between Bluesight and GraphiteRx. This alliance, which brings marketplace data into CostCheck and ShortageCheck, will help hospitals reduce drug spend and strengthen resilience amid ongoing shortages, according to a Bluesight news release.
Through the partnership, Bluesight customers can view Cost Plus Drugs pricing alongside traditional wholesaler options within their existing procurement decision workflows. This added visibility gives pharmacy teams greater flexibility when sourcing medications and making cost-based decisions. This addresses two of the most pressing challenges facing hospital pharmacies — rising drug costs and persistent shortages.
“By bringing alternative suppliers directly into the tools our customers use every day, we can create even more opportunities to balance cost, availability and reliability — especially at a time when healthcare organizations are facing significant financial pressure,” said Kevin MacDonald, CEO and cofounder of Bluesight.
More than three-quarters of hospital pharmacies identified reducing drug spend as a top priority in Bluesight’s Hospital Pharmacy Operations Report. A similar percentage of pharmacy leaders cited drug shortages as their most pressing operational challenge. As budgets tighten and reimbursement models evolve, the integration of the GraphiteRx marketplace provides hospitals:
- Expanded sourcing options. Cost Plus Drugs appears as an additional supplier within CostCheck and ShortageCheck, enabling real-time comparison of price alongside wholesalers and other sources.
- Greater sourcing flexibility. Accessing alternative suppliers with no volume commitments enables pharmacy teams to choose the best option by price, availability or clinical need.
- Stronger shortage resilience. Essential medications can be secured through additional supply channels when traditional distributors face constraints.
This collaboration reflects a shared commitment among technology and supply partners to bring greater transparency and efficiency into hospital procurement workflows.
“As drug costs rise and shortages persist, hospitals need more options they can trust,” said David Zilberman, founder and CEO of GraphiteRx. “This collaboration represents the kind of ecosystem the health care supply chain needs. By bringing together technology, marketplace access and transparent pricing, hospitals have more leverage on cost and availability and can make affordable, reliable medication access the norm, not the exception.”
Alan Bowe, chief commercial officer for Mark Cuban Cost Plus Drugs, agrees.
“Health care providers need trusted partners who can help them navigate an increasingly complex supply chain,” he said. “Our partnership with Bluesight through the GraphiteRx platform brings transparency and affordability directly into the workflows where sourcing decisions happen. Together, we’re making it easier for hospitals to access the medications their patients need at prices that make sense.”